NaNotics, LLC is a privately held company based in Mill Valley, CA, currently raising a Series B funding round. NaNotics is developing a new method of treating cancer: a novel class of injectable nanoparticles – called NaNots – that scavenge tumor-generated immune inhibitors from circulation, creating a “diffusion sink” that induces migration of inhibitors from the tumor microenvironment (TME) – enabling immune response and tumor regression. Cancers surround themselves with these molecules, which limit efficacy of cancer immunotherapies. NaNots hold promise as both mono- and adjunctive therapies. The company has both in vitro and in vivo (mouse) data on efficacy. NaNotics is also engineering a set of NaNots against specific inflammatory cytokines that drive both acute and chronic autoimmune and auto-inflammatory disorders. The NaNot platform is the subject of 3 granted patents and 7 pending patents.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Set of 6 "NaNots" – nano scavengers – against molecular targets active in cancer and other diseases
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):